Platform for discovery of novel antifungal therapeutics

Focusing on tackling the problem of resistance to current antifungal therapies via the development of new drugs for infectious diseases

Calira Therapeutics is Cambridge based biotech focused on allosteric inhibitors of CaMK2 for the treatment of diabetes and heart failure.  By pursuing allosteric inhibition at a novel binding site identified by the Calira team, selective and safe inhibitors of CaMK2 can be advanced into the clinic.

Developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, is expected to enter Phase I in 2021 in advanced solid tumors.

Cardiovascular disease （PCSK9）

Oral PCSK9 Inhibitors for the Treatment of Cardiovascular Disease

https://www.dogmatherapeutics.com/

Enable RNA therapeutics beyond the liver

Developing a technology that enables delivery of RNAi (double-stranded oligonucleotide) therapeutics to multiple cell types and tissues

Focusing on the discovery and development of specific Caspase inhibitors for nonalcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) therapy and other inflammatory conditions.

Epican focuses on cancer screening and clinical testing. The red chip construction has completed in the following financing. Epican is dedicated to the development of detection based on 5hmc DNA methylation for early cancer screening and clinical test, which was patented from the university of Chicago. 早易安 have been put on the market, and the clinical test kit for early cancer screening for liver cancer has been declared.

Developing proprietary oral slow-release formulation of 5-HTP and low-dose carbidopa for anti-depression